OTO, is one of several early-stage gene therapies being developed to treat relatively straight-forward causes of genetic ...

Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that it has completed its previously announced ...

Hyderabad: Cell and gene therapy solutions provider Miltenyi Biotec on Monday announced the roll-out of what is touted as ...

Regeneron Pharmaceuticals said on Monday its experimental gene therapy showed improved hearing in 10 of 11 children between ...

In January 2025, various US Food and Drug Administration (FDA) centers and offices published their guidance agendas for the 2025 calendar year ...

Regeneron’s gene therapy, dubbed DB-OTO, is a cell-selective AAV gene therapy for children with hearing loss stemming from a ...

Neurogene Inc. (NASDAQ: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neu ...

"We have, for the first time, an effective treatment for the most severe form of childhood blindness, and a potential ...

Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.

Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative ...

Miltenyi Biotec launched India's first Cell and Gene Therapy Center in Hyderabad. The Miltenyi Innovation and Technology ...

MeiraGTx is advancing its investigational gene therapy toward expedited approval in the UK after 11 children who were born ...